Regenerative orthopedics trend: BMC and PRP

Platelet-rich plasma and bone marrow concentrate are moving deeper into sports orthopedics, but the evidence still fits symptom relief better than true tissue regrowth. (sportsmed.org) Platelet-rich plasma starts with a blood draw, then a centrifuge spins down the sample to concentrate platelets and the growth-factor proteins they release during healing. Bone marrow aspirate concentrate starts with marrow taken through a needle, then processed into a denser mix of cells and signaling proteins before injection. (sportsmed.org) (my.clevelandclinic.org) Sports medicine doctors use both approaches for joints, cartilage, tendons, ligaments and some bone-healing problems because they can be done as outpatient procedures with a patient’s own tissue. Cleveland Clinic says bone marrow aspirate concentrate is being used experimentally across muscles, bones, cartilage, tendons and ligaments, while the American Orthopaedic Society for Sports Medicine describes platelet-rich plasma as an “orthobiologic” aimed at supplementing healing. (my.clevelandclinic.org) (sportsmed.org) The current evidence base is strongest in knee osteoarthritis, where a 2024 network meta-analysis pooled 48 studies and 9,338 knees. It found platelet-rich plasma, bone marrow aspirate concentrate and hyaluronic acid ranked ahead of corticosteroid injections for pain or function at six months or longer. (pubmed.ncbi.nlm.nih.gov) That same literature does not show bone marrow concentrate clearly beating platelet-rich plasma. A prospective randomized trial published in 2022 reported that bone marrow aspirate concentrate and platelet-rich plasma performed similarly for knee osteoarthritis through 24 months. (pubmed.ncbi.nlm.nih.gov) Reviews published in 2025 say the gap between enthusiasm and proof remains wide for bone marrow concentrate. One review in *Tissue Engineering and Regenerative Medicine* said bone marrow aspirate concentrate has gained acceptance as a safe orthobiologic for osteoarthritis despite “lacking robust supporting evidence,” and said structural improvement is seldom reported. (link.springer.com) That distinction matters in sports injuries because pain relief and actual repair are not the same outcome. The American Orthopaedic Society for Sports Medicine’s 2024 review said platelet-rich plasma may help symptoms in knee osteoarthritis, but it also described the literature on the best formulation and the overall strength of support as mixed. (sportsmed.org) Regulators have also drawn a line between office-based use and approved regenerative products. The Food and Drug Administration said in a June 3, 2021 consumer alert that many regenerative medicine products marketed for pain and orthopedic conditions are unapproved, and that products offered outside an FDA-supervised clinical trial may be marketed illegally. (fda.gov) Professional groups are still trying to sort the field by indication, not hype. The American Academy of Orthopaedic Surgeons maintains separate technology overviews for platelet-rich plasma and concentrated bone marrow aspirate in knee osteoarthritis, a sign that the question in 2026 is less whether these injections exist than where, exactly, they work well enough to justify the cost and procedure. (aaos.org)